<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04137510</url>
  </required_header>
  <id_info>
    <org_study_id>C1703</org_study_id>
    <nct_id>NCT04137510</nct_id>
  </id_info>
  <brief_title>Bioflow-DAPT Study</brief_title>
  <official_title>A Prospective, Randomized, Multi-center Study to Assess the Safety of the Orsiro Mission Stent Compared to the Resolute Onyx Stent in Subjects at High Risk for Bleeding in Combination With 1-month Dual Antiplatelet Therapy (DAPT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BIOFLOW-DAPT is a prospective, multi-center, international, two-arm randomized controlled
      clinical study.

      A total of 1'948 subjects will be randomized 1:1 to receive either Orsiro or Resolute Onyx.
      After index procedure, all patients will receive DAPT (ASA + P2Y12 inhibitor) for 30 days,
      followed by monotherapy with either P2Y12 inhibitor or ASA only until the end of the study.

      Clinical follow-up visits will be scheduled at 1, 6 and 12 months post-procedure.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multi-center, international, two-arm randomized controlled clinical study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of cardiac death, myocardial infarction (MI) and definite or probable stent thrombosis at 12 months</measure>
    <time_frame>12 months post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of definite/probable stent thrombosis according to the ARC definition</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MACCE</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>composite of all-cause death, MI, and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of MACE</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>composite of cardiac death, MI, and Target Vessel Revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiac death or MI</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>all, target vessel related MI, Q-wave and non Q-wave, ST-related and non ST-related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of all-cause death, cardiac, non-cardiac</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stroke, ischemic and hemorrhagic</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically-indicated TVR</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically-indicated Target Lesion Revascularization (TLR)</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Target Vessel Failure (TVF)</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>Composite of clinically-driven TVR, cardiac death or target-vessel related MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of target lesion failure (TLF)</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>Composite of clinically driven TLR, cardiac death or target vessel related MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bleeding according to BARC definition</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bleeding according to GUSTO definition</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bleeding according to TIMI definition</measure>
    <time_frame>until 12 months post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Device success</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>Attainment of less than 30% residual stenosis of the target lesion using assigned stent only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Procedure success</measure>
    <time_frame>until 12 months post-procedure</time_frame>
    <description>Attainment of less than 30% residual stenosis of the target lesion using assigned stent only without occurrence of in-hospital major adverse cardiac events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1948</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Resolute Onyx</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Percutaneous coronary intervention</intervention_name>
    <description>It's a non-surgical procedure that uses a catheter to place a stent into a coronary blood vessel in order to open up the vessel.</description>
    <arm_group_label>Orsiro</arm_group_label>
    <arm_group_label>Resolute Onyx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is acceptable candidate for treatment with a DES

          2. Subject is considered at high bleeding risk (HBR), defined as meeting one or more of
             the following criteria at the time of enrollment:

               1. ≥ 75 years of age

               2. Moderate (estimated GFR 30-59 ml/min) or severe (estimated GFR &lt; 30 ml/min)
                  chronic kidney disease or failure (dialysis dependent)

               3. Advanced liver disease, defined as having cirrhosis with or without portal
                  hypertension and with or without gastroesophageal varices.

               4. Cancer (excluding non-melanoma skin cancer) diagnosed or treated within the
                  previous 12 months or actively treated

               5. Anemia with hemoglobin &lt; 11.0 g/dL or requiring transfusion within 4 weeks prior
                  to randomization

               6. Baseline thrombocytopenia defined as a platelet count &lt;100,000/mm3

               7. History of stroke (ischemic or hemorrhagic), or brain arteriovenous malformation

               8. History of hospitalization for bleeding within the previous 12 months

               9. Chronic clinically significant bleeding diathesis

              10. Clinical indication for chronic or lifelong oral anticoagulation (OAC) (with a
                  vitamin K antagonist or non-vitamin K OAC)

              11. Clinical indication for chronic or lifelong steroid or oral nonsteroidal
                  anti-inflammatory drug(s) (NSAIDs), other than aspirin

              12. Nondeferrable major surgery on DAPT

              13. Recent major surgery or major trauma within 30 days before PCI

              14. Precise DAPT score ≥ 25

          3. Subject is ≥ 18 years or the minimum age required for legal adult consent in the
             country of enrollment

          4. Subject is capable (no legally authorized representative allowed) to provide written
             informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee
             (EC) of the respective clinical site prior to any study related procedure

          5. Subject is willing to comply with all protocol and follow-up requirements, including
             agreement to discontinue DAPT at 1 month

          6. Subject is eligible for dual antiplatelet therapy treatment with aspirin plus a P2Y12
             inhibitor agent for 1-month post index procedure

        Exclusion Criteria:

          1. Subject who previously experienced a stent or scaffold thrombosis in any coronary
             vessel

          2. Subject has a known allergy to all types of P2Y12 inhibitor (Clopidogrel, Ticagrelor,
             Prasugrel, Ticlopidine and Cangrelor; thus preventing the use of the appropriate P2Y12
             inhibitor), aspirin, both heparin and bivalirubin, L-605 cobalt-chromium (Co-Cr) alloy
             or one of its major elements (cobalt, chromium, tungsten and nickel), silicon carbide,
             PLLA, Sirolimus, or contrast media

          3. Revascularization of any target vessel within 9 months prior to the index procedure or
             previous PCI of any non-target vessel within 72 hours prior to or during the index
             procedure

          4. Subject with documented left ventricular ejection fraction (LVEF) &lt;30% as evaluated by
             the most recent imaging exam (i.e. echocardiogram, ventriculogram, MUGA, etc.)

          5. Subject judged by physician as inappropriate for discontinuation from DAPT at 1 month
             following index procedure, due to another condition requiring chronic DAPT

          6. Subject with planned surgery or procedure necessitating discontinuation of P2Y12
             inhibitor and/or aspirin within the first month post-index procedure Note - planned
             staged procedure at the time of index procedure is not allowed

          7. Active bleeding at the time of inclusion

          8. Subject with a current medical condition with a life expectancy of less than 12 months

          9. Subject is currently participating or intends to participate in another
             investigational drug or device trial within 12 months following the index procedure or
             any other clinical trial that may interfere with the treatment or protocol of this
             study

         10. Subject is pregnant and/or breastfeeding or intends to become pregnant during the
             duration of the study

         11. In the investigator's opinion, subject will not be able to comply with the follow-up
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Valgimigli, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Structural Heart Disease, University Hospital for Cardiology, Inselspital Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olga Neklyudova, PhD</last_name>
    <phone>+41 44 864 51 87</phone>
    <email>olga.neklyudova@biotronik.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara Galeuchet-Schenk, PhD</last_name>
    <phone>+41 44 864 53 59</phone>
    <email>barbara.galeuchet-schenk@biotronik.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabor Toth, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mathias-Christoph Brandt, Doz. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev og Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Niels Thue Olsen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roskilde University Hospital</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henning Kelbaek, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ralph Tölg, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Neuss, Lukaskrankenhaus GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>41464</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Haude, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1124</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Béla Merkely, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan-Fernando Iglesias, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaires Vaudoise</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephane Fournier, Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Franz R. Eberli, PRof. Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 22, 2019</study_first_submitted>
  <study_first_submitted_qc>October 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2019</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DAPT</keyword>
  <keyword>Dual antiplatelet therapy</keyword>
  <keyword>high bleeding risk</keyword>
  <keyword>HBR</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

